Izvorni znanstveni članak

Prevention of cytomegalovirus infection after kidney transplantation

Ivana Mikolašević ; Zavod za nefrologiju, dijalizu i transplantaciju bubrega, KBC Rijeka, Rijeka
Vojko Mavrinac ; Zavod za gastroenterologiju, KBC Rijeka, Rijeka
Marina Colić ; Zavod za nefrologiju, dijalizu i transplantaciju bubrega, KBC Rijeka, Rijeka
Ksenija Jozić ; Zavod za nefrologiju, dijalizu i transplantaciju bubrega, KBC Rijeka, Rijeka
Sanjin Rački ; Zavod za nefrologiju, dijalizu i transplantaciju bubrega, KBC Rijeka, Rijeka
Dragana Krbavac ; Zavod za nefrologiju, dijalizu i transplantaciju bubrega, KBC Rijeka, Rijeka
Vesna Babić ; Zavod za nefrologiju, dijalizu i transplantaciju bubrega, KBC Rijeka, Rijeka
Lidija Orlić ; Zavod za nefrologiju, dijalizu i transplantaciju bubrega, KBC Rijeka, Rijeka

Sažetak

Introduction: According to the current guidelines prophylactic treatment for Cytomegalovirus (CMV) is recommended in solid organ transplantation. We were interested to explore the prevalence of CMV viremia/disease due to use of prophylactic treatment in our renal transplant recipients (RTRs). Patients and methods: We retrospectively examined the 24-year (from 01.01.1990 to 31.12.2014) data of 521 RTRs mean age 48.9 ± 13.6 years. 95 RTRs were received prophylaxis for CMV and 426 patients didn’t receive prophylactic treatment. Results: Prophylactic treatment significantly reduced the incidence of CMV disease during the first-year after transplantation (2.1 % vs. 8.7 %; P = 0.046). Although the prevalence of CMV viremia was higher in the group of patients that didn’t receive prophylaxis, that difference was not statistically significant (3.2 % vs. 9.4 %; P = 0.073). The mean values of serum creatinine didn’t show any significant differences after one-year of follow-up between the RTRs who received prophylaxis in comparison to the patients that didn’t receive prophylactic treatment (131.1 ± 66.4 vs. 145.6 ± 88.5; P = 0.173). Although the loss of renal allograft was higher in the group of patients that didn’t receive prophylactic treatment, that difference was not statisticaly significant. In the group of patients who received prophylaxis the main reasons for graft loss were an acute rejection and surgical complications, while surgical complications and chronic allograft nephropathy were the most common reasons for graft loss in the second group of RTRs. Conclusion: Prophylactic treatment with vanganciklovir for CMV is an effective way to prevent CMV disease after renal transplantation.

Ključne riječi

cytomegalovirus infection; prophylaxis; transplantation

Hrčak ID:

152995

URI

https://hrcak.srce.hr/152995

Datum izdavanja:

1.3.2016.

Podaci na drugim jezicima: hrvatski

Posjeta: 1.922 *